Toggle navigation
Home
Search
Services
Blog
Contact
About
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara
Biocryst Pharmaceuticals, Inc., Birmingham, AL, United States
Search 146 grants from Y Babu
Search grants from Biocryst Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Improving prevention of mother-to-child HIV transmission outcomes in Malawi
Training Biostatisticians in Psychiatric Research
Computer Hardware for Sequence Analysis
Platelet Activating Factor Signaling in Liver
Post Coronary Artery Bypass Graft Study
Recently added grants:
A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors
The Impact of Tobacco Control Policies on Health Equity in the United States
Safer Approaches to CRC Chemoprevention
Exploring the shared genetic architecture of white blood cell variation and childhood acute lymphoblastic leukemia
DNA damage signaling to dormant origins of replication
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AR041095-03
Application #
2080467
Study Section
Special Emphasis Panel (ZRG7-SSS-6 (06))
Project Start
1994-02-16
Project End
1996-02-15
Budget Start
1995-04-05
Budget End
1996-02-15
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Biocryst Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
Related projects
NIH 1995
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
NIH 1994
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant